BioMarin Pharmaceutical Inc. (BMRN) Position Increased by Seven Eight Capital LP

(NASDAQ:BMRN) by 20.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,298 shares of the biotechnology company's stock after acquiring an additional 5,002 shares during the quarter. Aperio Group has an ownership of 56,491 stocks of the biotechnology firms shares valued $5,131,000 following acquiring an extra 5,006 shares through out the previous quarter, Emory University lifted its holdings in BioMarin Pharmaceutical by 3.2% through out the 1st period.

Several other institutional investors have also recently bought and sold shares of BMRN. Primecap Management Co. CA lifted its position in BioMarin Pharmaceutical by 10.5% during the 1st quarter. Parallel Advisors LLC now owns 1,042 shares of the biotechnology company's stock valued at $100,000 after buying an additional 125 shares during the period. The Bermuda-based Btg Pactual Global Asset Management Ltd has invested 8.44% in the stock. LLC grew its stake in shares of BioMarin Pharmaceutical by 59.7% in the 1st quarter. Korea Investment CORP grew its stake in shares of BioMarin Pharmaceutical by 143.5% in the 2nd quarter. Ltd. now owns 74,103 shares of the company's stock valued at $6,856,000 after buying an additional 16,012 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in BioMarin Pharmaceutical by 4.7% during the 2nd quarter. Primecap Management Co. CA now owns 8,712,268 shares of the biotechnology company's stock worth $764,763,000 after acquiring an additional 826,320 shares during the last quarter.

BioMarin Pharmaceutical Inc., launched on October 25, 1996, is a biotechnology company. (NASDAQ:BMRN) were released by: and their article: "3 Big Stock Charts for Wednesday: Twilio Inc (TWLO), BioMarin Pharmaceutical ..." published on August 23, 2017 as well as's news article titled: "BioMarin (BMRN) Up 2.5% Since Earnings Report: Can It Continue?" with publication date: September 07, 2017. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and global copyright laws. The correct version of this piece of content can be read at The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares saw heavy trading volume with 1,213K shares changing hands in the last trading session. BioMarin Pharmaceutical has a 52 week low of $78.42 and a 52 week high of $101.27. BioMarin Pharmaceutical Inc. The firm has a 50 day moving average of $86.72 and a 200 day moving average of $89.48.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Wednesday, August 2nd.

As of the last earnings report the EPS was $-1.07 and is projected to be $-0.71 for the current year with 175,268,000 shares outstanding. BioMarin Pharmaceutical had 62 analyst reports since August 5, 2015 according to SRatingsIntel. The business had revenue of $317.50 million for the quarter, compared to analysts' expectations of $311.41 million. During the same quarter in the previous year, the firm earned ($2.61) earnings per share. The company's revenue for the quarter was up 5.8% on a year-over-year basis. The Ohio-based Victory Capital Mngmt Inc has invested 0.3% in BioMarin Pharmaceutical Inc.

In other news, SVP Brian Mueller sold 2,671 shares of the firm's stock in a transaction on Thursday, June 22nd. (NASDAQ:BMRN) shares with value of $655,377 were sold by BIENAIME JEAN JACQUES. Following the completion of the transaction, the senior vice president now directly owns 15,556 shares of the company's stock, valued at $1,555,600. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

In other news, EVP George Eric Davis sold 9,844 shares of the company's stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $90.50, for a total transaction of $1,357,500.00. Following the transaction, the chief executive officer now owns 174,682 shares in the company, valued at $14,603,415.20. The disclosure for this sale can be found here. Two financial stock experts recommended the company shares with a sell recommendation, around ten have issued a hold recommendation and fifteen have issued a buy recommendation to the share. Insiders own 2.50% of the company's stock.

A number of brokerages have recently commented on BMRN. Sanford C. Bernstein assumed coverage on shares of BioMarin Pharmaceutical in a research note on Thursday, July 27th. The firm issued an overweight rating and a $113.00 price objective on the biotechnology company's stock. Evercore ISI started coverage on shares of BioMarin Pharmaceutical in a report on Wednesday, August 16th. Royal Bank of Canada began coverage on BioMarin Pharmaceutical in a research report on Thursday, September 14th. They set an outperform rating and a $100.00 price objective on the stock. SunTrust Banks, Inc. restated a "buy" rating and issued a $115.00 price objective on shares of BioMarin Pharmaceutical in a report on Friday, July 14th. Barclays Capital has "Equal-Weight" rating and $105 target. BioMarin Pharmaceutical presently has an average rating of Hold and a consensus target price of $109.09. Swiss National Bank lifted its holdings in BioMarin Pharmaceutical by 3.6% through out the 2nd period.

ZIOPHARM Oncology, a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company's product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates.

Like this


21 September 2017
KPMG is cleared over HBOS audit
KPMG "considered and accepted this conclusion" and HBOS published its accounts in February 2008 on that basis, the FRC said. A spokesperson for KPMG said the firm was "pleased" with the conclusion of the investigation.

21 September 2017
Gerry Ritz apologizes for calling environment minister 'climate Barbie'
Tory MP Michelle Rempel, who has spoken out about the sexism women often face in politics , also weighed in Tuesday night. Maryam Monsef, minister for the status of women, took to Twitter to call out Ritz's "gender-based name-calling".

21 September 2017
Catch up on last night's Emmy Awards with these 5 graphics
He said: "The big winners last night were Donald Glover , Hulu and former White House press secretary Sean Spicer ". However, President Trump aired his feelings on the show while slamming what he perceived as bad ratings.

21 September 2017
Today's Brokerage Rating: Intel Corporation (INTC), Snap Inc. (SNAP)
Finally, Stockman Wealth Management Inc. boosted its position in shares of Intel Corporation by 2.3% during the first quarter. Intel Corporation ( INTC ) have shown a high EPS growth of -2.40% in the last 5 years and has earnings decline of -9.30% yoy.

21 September 2017
Merkel condemns Trump's North Korea threat
Trump threatened to " totally destroy " North Korea if it continued with its nuclear arms development, but Merkel said sanctions are "the right answer".

21 September 2017
Duterte offers to host office of UN rights monitor
Duterte added that P600 million is enough to buy state-of-the-art cameras the size of a button that all policemen can wear 24 hours a day.

21 September 2017
CEO's Sexist Tirade Against Neighbor Kathy Griffin Was Caught on Tape
It was a security camera that caught Mezger screaming the insults- initially at Griffin's boyfriend Randy Bick . According to the Post, Mezger's tirade came after Griffin and Bick called police to report a noise disturbance.

21 September 2017
Yoko Ono Breaks Up John Lemon Lemonade Company
Mr Chamera said he is being forced to sell all his stock of the drink before the ban comes into force on October 30. Ono Lennon's lawyers said the lemonade infringed the trademark of her late husband's name and his personal rights.

21 September 2017
Ali Fazal's Victoria & Abdul Releases In The UK, Gets A Thumbs Up
She is one of the most attractive women I have ever laid my eyes on. "I learnt a lot from her". The movie has been directed by Stephen Frears and has been distributed by Focus Features.

21 September 2017
Titans sign receiver Zach Pascal, put LB Aaron Wallace on IR
Seaton replaces offensive lineman Tyler Marz, who was signed off the Titans' practice squad by the Los Angeles Chargers. The Maryland native left ODU as the all-time leading receiver with 233 receptions for 3,193 yards and 30 touchdowns.